skip to main content
Lingue:

Malignant testicular germ cell tumors in children and adolescents: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) protocol

Terenziani, Monica ; De Pasquale, Maria D ; Bisogno, Gianni ; Biasoni, Davide ; Boldrini, Renata ; Collini, Paola ; Conte, Massimo ; Dall'Igna, Patrizia ; Inserra, Alessandro ; Melchionda, Fraia ; Siracusa, Fortunato ; Spreafico, Filippo ; Barretta, Francesco ; D'Angelo, Paolo

Urologic oncology, November 2018, Vol.36(11), pp.502.e7-502.e13 [Rivista Peer Reviewed]

Fulltext disponibile

Citazioni Citato da
  • Titolo:
    Malignant testicular germ cell tumors in children and adolescents: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) protocol
  • Autore: Terenziani, Monica ; De Pasquale, Maria D ; Bisogno, Gianni ; Biasoni, Davide ; Boldrini, Renata ; Collini, Paola ; Conte, Massimo ; Dall'Igna, Patrizia ; Inserra, Alessandro ; Melchionda, Fraia ; Siracusa, Fortunato ; Spreafico, Filippo ; Barretta, Francesco ; D'Angelo, Paolo
  • Note di contenuto: We report the results of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) study on the treatment of testicular germ cell tumors (TGCT) with a pediatric PEB (pPEB) regimen (cisplatin 25 mg/m daily on days 1-4; etoposide 100 mg/m daily on days 1-4; bleomycin 15 mg/m on day 2, once per cycle). Male patients under 18 years old with malignant TGCT were enrolled for a second national prospective protocol. All patients underwent orchiectomy at diagnosis. Those with Stage I received no chemotherapy; those with Stage II-III disease received three cycles of pPEB; and those with Stage IV received four cycles. After chemotherapy, resection of radiologically-evident residual disease was recommended. The main study end-points were overall survival and relapse-free survival. Ninety-nine boys from 0.5 to 17.8 years old (median 15.4 years) were evaluable, and staged as follows: 58 Stage I (59%), 7 Stage II (7%), 14 Stage III (14%), and 20 Stage IV (20%). With a median follow-up of 59 months (range 4-165 months), 5-year relapse-free survival (95% CI) was 73% (65%-83%) for the whole sample, 65% (53%-79%) for Stage I patients, and 86% (75%-98%) for Stage II-IV patients. Five-year overall survival (95% CI) was 99% (97%-100%). We confirmed a good prognosis for malignant TGCT in children and adolescents. Reducing the number of chemotherapy cycles for Stage II-III disease does not seem to negatively affect survival outcomes.
  • Fa parte di: Urologic oncology, November 2018, Vol.36(11), pp.502.e7-502.e13
  • Soggetti: Adolescents ; Children ; Germ Cell Tumors ; Testis ; Antineoplastic Combined Chemotherapy Protocols -- Therapeutic Use ; Neoplasms, Germ Cell and Embryonal -- Drug Therapy ; Testicular Neoplasms -- Drug Therapy
  • Lingua: Inglese
  • Tipo: Articolo
  • Identificativo: E-ISSN: 1873-2496 ; PMID: 30249520 Version:1 ; DOI: 10.1016/j.urolonc.2018.07.001
  • Fonte: MEDLINE/PubMed (U.S. National Library of Medicine)

Ricerca in corso nelle risorse remote ...